FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171317614> ?p ?o ?g. }

• W2171317614 endingPage "172" @default.
• W2171317614 startingPage "167" @default.
• W2171317614 abstract "Sixteen patients with aggressive primary testicular involvement were analyzed separately from a prospective multicenter series of 494 patients with stage I/II aggressive nonlymphoblastic lymphoma. The treatment strategy included 3 cycles of anthracycline-based chemotherapy followed by regional radiation therapy on inguinal, iliac, and para-aortic lymph nodes and central nervous system (CNS) prophylaxis by intrathecal chemotherapy and brain irradiation. Chemotherapy was stratified by age group. Patients aged 18-60 years received the Groupe Ouest Est d'Etude des Leucemies Aigues et Maladies du Sang (GOELAMS) 02 protocol: 3 monthly cycles of VCAP (vindesine 3 mg/m2 day 1, doxorubicin 80 mg/m2 day 2, cyclophosphamide 1500 mg/2 day 2, and prednisone 80 mg/2 days 1–5). Patients aged 61–75 years received the GOELAMS 03 protocol: 3 monthly cycles of VECP-Bleo (vindesine 3 mg/2 day 1, epirubicin 60 mg/2 day 1, cyclophosphamide 750 mg/2 day 1, prednisone 50 mg/2 days 1–7, and bleomycin 10 mg/2 days 1 and 5). Sixteen patients had testicular involvement (3.3%). Median age was 62 years (range, 29–73 years). The histological subtypes were diffuse large-cell lymphoma in all cases. Ann Arbor stage was IEA in 11 patients, IEB in 3 patients, and IIEA in 2 patients. All patients achieved a complete response. One patient died from septic shock during the last course of chemotherapy. After a median follow-up period of 73.5 months, the probability of disease-free survival (DFS) and overall survival (OS) were 70% and 65%, respectively for all patients. Disease-free survival and OS were 66% and 83% in patients > 60 years of age, and 74% and 56% in patients > 60 years of age. Relapse occurred in extranodal sites in 4 cases and in abdominal lymph nodes in the last case. Relapse in the CNS occurred in only 1 patient and in the contralateral testis in 1 patient. We found no correlation between OS, DFS and extent of testicular involvement, Ann Arbor stage, International Prognostic Index score, or lactate dehydrogenase level. This is the first report of a prospective study in which treatment of testicular non-Hodgkin's lymphoma was precisely defined at diagnosis. Compared to other series, a combination of orchiectomy with 3 cycles of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-derived chemotherapy, regional radiation therapy, and CNS prophylaxis seems to improve prognosis. The improvement in prognosis seemed to be due in part to irradiation, including the pelvic and lomboaortic lymphatic areas, and in part to CNS prophylaxis." @default.
• W2171317614 created "2016-06-24" @default.
• W2171317614 creator A5000074573 @default.
• W2171317614 creator A5002061358 @default.
• W2171317614 creator A5014723395 @default.
• W2171317614 creator A5016485718 @default.
• W2171317614 creator A5024819951 @default.
• W2171317614 creator A5032008939 @default.
• W2171317614 creator A5042002104 @default.
• W2171317614 creator A5046342676 @default.
• W2171317614 creator A5051670389 @default.
• W2171317614 creator A5083554802 @default.
• W2171317614 creator A5084447104 @default.
• W2171317614 creator A5087289242 @default.
• W2171317614 creator A5088832163 @default.
• W2171317614 date "2002-12-01" @default.
• W2171317614 modified "2023-09-27" @default.
• W2171317614 title "Stage I-IIE Primary Non-Hodgkin's Lymphoma of the Testis: Results of a Prospective Trial by the GOELAMS Study Group" @default.
• W2171317614 cites W11317782 @default.
• W2171317614 cites W1820202841 @default.
• W2171317614 cites W1884938169 @default.
• W2171317614 cites W1885131295 @default.
• W2171317614 cites W1964189774 @default.
• W2171317614 cites W2009095217 @default.
• W2171317614 cites W2025580210 @default.
• W2171317614 cites W2058484774 @default.
• W2171317614 cites W2074609762 @default.
• W2171317614 cites W2091679619 @default.
• W2171317614 cites W2098811452 @default.
• W2171317614 cites W2107202569 @default.
• W2171317614 cites W2119064166 @default.
• W2171317614 cites W2148917037 @default.
• W2171317614 cites W2172516575 @default.
• W2171317614 cites W2224137437 @default.
• W2171317614 cites W2229273361 @default.
• W2171317614 cites W2256325380 @default.
• W2171317614 cites W2414357472 @default.
• W2171317614 cites W4205736005 @default.
• W2171317614 cites W4252168887 @default.
• W2171317614 cites W4293241248 @default.
• W2171317614 doi "https://doi.org/10.3816/clm.2002.n.023" @default.
• W2171317614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12521394" @default.
• W2171317614 hasPublicationYear "2002" @default.
• W2171317614 type Work @default.
• W2171317614 sameAs 2171317614 @default.
• W2171317614 citedByCount "47" @default.
• W2171317614 countsByYear W21713176142012 @default.
• W2171317614 countsByYear W21713176142013 @default.
• W2171317614 countsByYear W21713176142014 @default.
• W2171317614 countsByYear W21713176142015 @default.
• W2171317614 countsByYear W21713176142016 @default.
• W2171317614 countsByYear W21713176142017 @default.
• W2171317614 countsByYear W21713176142018 @default.
• W2171317614 countsByYear W21713176142020 @default.
• W2171317614 countsByYear W21713176142021 @default.
• W2171317614 countsByYear W21713176142022 @default.
• W2171317614 countsByYear W21713176142023 @default.
• W2171317614 crossrefType "journal-article" @default.
• W2171317614 hasAuthorship W2171317614A5000074573 @default.
• W2171317614 hasAuthorship W2171317614A5002061358 @default.
• W2171317614 hasAuthorship W2171317614A5014723395 @default.
• W2171317614 hasAuthorship W2171317614A5016485718 @default.
• W2171317614 hasAuthorship W2171317614A5024819951 @default.
• W2171317614 hasAuthorship W2171317614A5032008939 @default.
• W2171317614 hasAuthorship W2171317614A5042002104 @default.
• W2171317614 hasAuthorship W2171317614A5046342676 @default.
• W2171317614 hasAuthorship W2171317614A5051670389 @default.
• W2171317614 hasAuthorship W2171317614A5083554802 @default.
• W2171317614 hasAuthorship W2171317614A5084447104 @default.
• W2171317614 hasAuthorship W2171317614A5087289242 @default.
• W2171317614 hasAuthorship W2171317614A5088832163 @default.
• W2171317614 hasConcept C126322002 @default.
• W2171317614 hasConcept C141071460 @default.
• W2171317614 hasConcept C2776694085 @default.
• W2171317614 hasConcept C2776755627 @default.
• W2171317614 hasConcept C2778476748 @default.
• W2171317614 hasConcept C2778720950 @default.
• W2171317614 hasConcept C2779321808 @default.
• W2171317614 hasConcept C2779338263 @default.
• W2171317614 hasConcept C2779429289 @default.
• W2171317614 hasConcept C2780039790 @default.
• W2171317614 hasConcept C2780964509 @default.
• W2171317614 hasConcept C71924100 @default.
• W2171317614 hasConcept C90924648 @default.
• W2171317614 hasConceptScore W2171317614C126322002 @default.
• W2171317614 hasConceptScore W2171317614C141071460 @default.
• W2171317614 hasConceptScore W2171317614C2776694085 @default.
• W2171317614 hasConceptScore W2171317614C2776755627 @default.
• W2171317614 hasConceptScore W2171317614C2778476748 @default.
• W2171317614 hasConceptScore W2171317614C2778720950 @default.
• W2171317614 hasConceptScore W2171317614C2779321808 @default.
• W2171317614 hasConceptScore W2171317614C2779338263 @default.
• W2171317614 hasConceptScore W2171317614C2779429289 @default.
• W2171317614 hasConceptScore W2171317614C2780039790 @default.
• W2171317614 hasConceptScore W2171317614C2780964509 @default.
• W2171317614 hasConceptScore W2171317614C71924100 @default.
• W2171317614 hasConceptScore W2171317614C90924648 @default.
• W2171317614 hasIssue "3" @default.

• next